Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Invested Capital (2020 - 2023)

Candel Therapeutics' Invested Capital history spans 4 years, with the latest figure at $29.1 million for Q3 2023.

  • For Q3 2023, Invested Capital fell 59.62% year-over-year to $29.1 million; the TTM value through Sep 2023 reached $29.1 million, down 59.62%, while the annual FY2022 figure was $67.7 million, 4.66% up from the prior year.
  • Invested Capital for Q3 2023 was $29.1 million at Candel Therapeutics, down from $34.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $83.8 million in Q1 2022 and bottomed at -$42.7 million in Q2 2021.
  • The 4-year median for Invested Capital is $37.7 million (2023), against an average of $29.7 million.
  • The largest YoY upside for Invested Capital was 525.13% in 2021 against a maximum downside of 245.63% in 2021.
  • A 4-year view of Invested Capital shows it stood at -$23.1 million in 2020, then surged by 380.33% to $64.7 million in 2021, then rose by 4.66% to $67.7 million in 2022, then plummeted by 56.99% to $29.1 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Invested Capital are $29.1 million (Q3 2023), $34.4 million (Q2 2023), and $40.9 million (Q1 2023).